Metformin Substitutes: When You Can't Take Metformin, What a Clinician Replaces It With

Key Takeaways

• A metformin substitute is a different prescription drug used when metformin is contraindicated or causes intolerable side effects.
• The most common substitutes for type 2 diabetes are GLP-1 receptor agonists (semaglutide, tirzepatide, dulaglutide), SGLT2 inhibitors (empagliflozin, dapagliflozin), and DPP-4 inhibitors (sitagliptin, linagliptin).
• For weight loss without diabetes, GLP-1 receptor agonists (semaglutide as Wegovy, tirzepatide as Zepbound) are the closest functional substitutes.
• Metformin is contraindicated when eGFR is below 30 mL/min/1.73m². For patients in that range, SGLT2 inhibitors and GLP-1 agonists are usually the safer substitutes.
• Substitution decisions belong to a clinician. The drug class that replaces metformin depends on your specific reason for stopping it.

Direct answer (40-60 words)

A metformin substitute is a different glucose-lowering drug that replaces metformin when it causes side effects or is contraindicated. The most common clinician choices are GLP-1 receptor agonists (semaglutide, tirzepatide), SGLT2 inhibitors (empagliflozin, dapagliflozin), and DPP-4 inhibitors (sitagliptin). Choice depends on kidney function, weight goals, and cardiovascular risk.

Table of contents

1. The 30-second answer
2. Why patients need a metformin substitute
3. The four reasons metformin gets replaced
4. Substitute drug classes ordered by clinical similarity
5. GLP-1 receptor agonists as a substitute
6. SGLT2 inhibitors as a substitute
7. DPP-4 inhibitors as a substitute
8. Sulfonylureas: an older option
9. For weight loss without diabetes
10. Combination therapy after metformin
11. Switching: how the transition works
12. FAQ

Why patients need a metformin substitute

Metformin is the standard first-line drug for type 2 diabetes. The American Diabetes Association recommends it for nearly every adult with newly diagnosed type 2 diabetes (ADA Standards of Care 2024). It is cheap, well-tolerated for most patients, has 60+ years of safety data, and has favorable effects on cardiovascular risk.

But about 20% to 30% of patients cannot take metformin long-term (Maruthur et al., Ann Intern Med 2016). Reasons include:

• Severe GI side effects (diarrhea, nausea, abdominal pain) that don't resolve with extended-release formulations
• Chronic kidney disease with eGFR below 30 mL/min/1.73m² (FDA contraindication)
• B12 deficiency from long-term use
• Lactic acidosis risk in patients with hepatic impairment, severe heart failure, or contrast dye exposure
• Pregnancy preferences (metformin is generally considered safe but some clinicians switch to insulin or GLP-1 agonists)

For these patients, a metformin substitute is the next clinical decision.

The four reasons metformin gets replaced

The reason for replacing metformin determines which substitute is most appropriate.

Reason 1: GI intolerance. The substitute should not also cause GI side effects. SGLT2 inhibitors and DPP-4 inhibitors are usually well-tolerated. GLP-1 agonists also cause GI symptoms but they are different in character (early-titration nausea that adapts) and many patients tolerate one class but not the other.

Reason 2: Kidney function below threshold. With eGFR below 30, metformin is contraindicated. SGLT2 inhibitors are first-choice substitutes because they protect kidney function. Some SGLT2 inhibitors (like dapagliflozin) have FDA approval for chronic kidney disease itself.

Reason 3: Inadequate glucose control. When metformin alone isn't lowering A1C enough, the question shifts from "substitute" to "add-on or switch." GLP-1 agonists and SGLT2 inhibitors provide larger A1C reductions than metformin (1.5% to 2.5% range vs metformin's 1% to 1.5%).

Reason 4: Weight goals. Metformin is roughly weight-neutral or modestly weight-losing. Patients who need significant weight loss along with glucose control benefit from switching or adding a GLP-1 agonist.

Substitute drug classes ordered by clinical similarity

Ranked from most metformin-like to least:

Class	Glucose lowering	Weight effect	CV benefit	Kidney safety	Cost (cash)
GLP-1 receptor agonists	High	Loss	Yes (some agents)	Safe at low eGFR	$$$
SGLT2 inhibitors	Moderate	Loss	Yes	Protective	$$$
DPP-4 inhibitors	Moderate	Neutral	Neutral	Safe	$$
Thiazolidinediones	Moderate	Gain	Mixed	Caution in CKD	$
Sulfonylureas	High	Gain	Neutral/mixed	Caution in CKD	$
Insulin	Very high	Gain	Neutral	Safe	$ to $$$

For most patients who need a metformin substitute, the choice narrows to a GLP-1 agonist or an SGLT2 inhibitor. Both lower glucose, both produce weight loss, both have cardiovascular and kidney benefits, and both are safer than older options for patients with CKD.

GLP-1 receptor agonists as a substitute

GLP-1 receptor agonists are the most-prescribed metformin substitutes in 2026. Examples:

• Semaglutide (Ozempic injectable for diabetes; Rybelsus oral tablet for diabetes; Wegovy injectable for weight loss)
• Tirzepatide (Mounjaro for diabetes; Zepbound for weight loss; technically a dual GLP-1/GIP agonist)
• Dulaglutide (Trulicity, weekly injection)
• Liraglutide (Victoza, daily injection)
• Exenatide (Bydureon BCise, weekly injection)

How they substitute for metformin:

• Lower A1C by 1.5% to 2.5% on average (semaglutide and tirzepatide are at the high end; older agents in the 1.0% to 1.5% range)
• Produce weight loss of 5% to 20% of body weight depending on agent and dose
• Slow gastric emptying, suppress appetite, increase post-meal insulin, and suppress glucagon
• Cardiovascular benefit confirmed in major trials: semaglutide (SUSTAIN-6, Marso et al., NEJM 2016), liraglutide (LEADER), dulaglutide (REWIND)

When GLP-1 agonists make sense as a metformin substitute:

• BMI 27+ with weight-loss goals
• Cardiovascular disease or high CV risk
• Need for stronger A1C lowering
• Kidney function below 30 mL/min/1.73m² (most GLP-1 agents are safe)

When they make less sense:

• History of medullary thyroid carcinoma or MEN-2 syndrome (boxed warning contraindication)
• History of pancreatitis
• Severe gastroparesis
• Insurance won't cover them and cash price is unaffordable

For more on individual GLP-1 agents, see /articles/comparison/ozempic-vs-mounjaro/.

SGLT2 inhibitors as a substitute

SGLT2 inhibitors block glucose reabsorption in the kidneys, causing excess glucose to be excreted in urine. Examples:

• Empagliflozin (Jardiance)
• Dapagliflozin (Farxiga)
• Canagliflozin (Invokana)
• Ertugliflozin (Steglatro)

How they substitute for metformin:

• Lower A1C by 0.5% to 1.0% on average
• Produce 2 to 5 kg weight loss
• Lower blood pressure (3 to 5 mmHg systolic)
• Demonstrated cardiovascular benefit: empagliflozin (EMPA-REG OUTCOME, Zinman et al., NEJM 2015), dapagliflozin (DAPA-HF), canagliflozin (CANVAS)
• Demonstrated kidney protection: dapagliflozin (DAPA-CKD, Heerspink et al., NEJM 2020), empagliflozin (EMPA-KIDNEY)

When SGLT2 inhibitors make sense as a metformin substitute:

• Heart failure with preserved or reduced ejection fraction
• Chronic kidney disease (especially with proteinuria)
• Atherosclerotic cardiovascular disease
• Weight loss is desired but GLP-1s are not tolerated or unaffordable
• Modest A1C reduction is sufficient

When they make less sense:

• History of recurrent UTIs or genital fungal infections (urinary glucose is a substrate)
• Type 1 diabetes or insulin-dependent type 2 diabetes (DKA risk)
• Volume depletion or hypotension
• eGFR below 20-25 mL/min/1.73m² (initiation thresholds vary by agent)

DPP-4 inhibitors as a substitute

DPP-4 inhibitors increase endogenous GLP-1 by blocking the enzyme that breaks it down. They are weaker than direct GLP-1 agonists but have a much milder side-effect profile. Examples:

• Sitagliptin (Januvia)
• Linagliptin (Tradjenta)
• Saxagliptin (Onglyza)
• Alogliptin (Nesina)

How they substitute for metformin:

• Lower A1C by 0.5% to 0.8% on average
• Weight-neutral
• Once-daily oral tablet
• No cardiovascular benefit (also no harm in most agents; saxagliptin had a heart-failure signal in SAVOR-TIMI)

When DPP-4 inhibitors make sense as a metformin substitute:

• Patient prefers oral over injectable
• GI side effects of metformin or GLP-1 agonists were intolerable
• Modest A1C lowering is enough
• CKD: linagliptin needs no dose adjustment at any eGFR

When they make less sense:

• A1C is 8.5% or higher (DPP-4 lowering is modest)
• Weight loss is a goal
• Cost is a primary concern (DPP-4s are usually more expensive than older oral agents but cheaper than GLP-1s)

Sulfonylureas: an older option

Sulfonylureas (glipizide, glimepiride, glyburide) stimulate the pancreas to release more insulin. They are the cheapest non-metformin oral diabetes drugs.

Pros:

• Strong A1C lowering (1.0% to 2.0%)
• Generic, low cash price ($4 to $20/month)
• Long track record

Cons:

• Hypoglycemia risk (especially glyburide in older adults)
• Modest weight gain (2 to 5 kg)
• No cardiovascular or kidney benefit
• Beta-cell exhaustion over time, leading to loss of efficacy

Sulfonylureas were once the first-line substitute for metformin. Current ADA guidelines prefer GLP-1 agonists and SGLT2 inhibitors first, especially for patients with cardiovascular or kidney disease. Sulfonylureas remain useful when cost is the dominant factor.

For weight loss without diabetes

Metformin is sometimes prescribed off-label for weight loss in non-diabetic patients (especially those with PCOS or insulin resistance). The substitute landscape changes when diabetes is not the indication.

GLP-1 receptor agonists approved for weight management:

• Semaglutide 2.4 mg (Wegovy). FDA-approved 2021 for chronic weight management in adults with BMI 30+ or 27+ with comorbidity
• Tirzepatide (Zepbound). FDA-approved 2023 for the same indication
• Liraglutide 3 mg (Saxenda). FDA-approved daily injection

These are the most direct substitutes for off-label metformin weight-loss prescriptions. They produce significantly more weight loss than metformin (5% to 20% vs 2% to 5% on metformin).

Naltrexone-bupropion (Contrave) and phentermine-topiramate (Qsymia) are also FDA-approved weight-loss options. They work through different mechanisms (appetite suppression and reward pathway modulation) and produce less weight loss than GLP-1 agonists on average.

For more on the weight-loss agents, see /articles/glp1-hub/who-qualifies-for-glp1-medications.

Combination therapy after metformin

When metformin is "stopped" but another drug is added, the question shifts from substitution to combination. Common combinations after metformin:

• Metformin + GLP-1 agonist (when GI tolerance allows; standard ADA recommendation)
• Metformin + SGLT2 inhibitor
• Metformin + GLP-1 agonist + SGLT2 inhibitor (triple therapy for poor control)
• Metformin + DPP-4 inhibitor (when A1C only modestly elevated)

Patients sometimes hear "you need to stop metformin" when they actually mean "we're adding something." Worth clarifying with the prescriber. True substitution is reserved for cases where metformin is contraindicated or genuinely intolerable.

Switching: how the transition works

The mechanics of switching from metformin to a substitute:

To a GLP-1 agonist. Stop metformin and start GLP-1 at the labeled starting dose (e.g., semaglutide 0.25 mg, tirzepatide 2.5 mg) the next day or week. No wash-out needed. Titrate up over 4 to 16 weeks. Recheck A1C at 3 months.

To an SGLT2 inhibitor. Stop metformin and start SGLT2 at full dose (e.g., empagliflozin 10 mg) the next day. Verify eGFR is above the threshold for the chosen agent. Recheck A1C at 3 months.

To a DPP-4 inhibitor. Stop metformin and start DPP-4 at full dose (e.g., sitagliptin 100 mg) the next day. Adjust dose for renal function (linagliptin doesn't need adjustment).

To a sulfonylurea. Stop metformin and start sulfonylurea at low dose (e.g., glipizide 2.5 mg). Monitor blood glucose closely for hypoglycemia, especially in older adults.

The transition typically does not require a temporary glucose spike. If A1C rises during the switch, the substitute may be under-dosed, or the patient may benefit from combination therapy rather than substitution.

FAQ

What is the best metformin substitute? Depends on your situation. For type 2 diabetes with weight-loss goals or cardiovascular disease: a GLP-1 agonist (semaglutide, tirzepatide). For type 2 diabetes with kidney disease or heart failure: an SGLT2 inhibitor (empagliflozin, dapagliflozin). For mild diabetes with cost concerns: a DPP-4 inhibitor or sulfonylurea.

What can I take instead of metformin for type 2 diabetes? The mainstream substitutes are GLP-1 receptor agonists (Ozempic, Mounjaro, Trulicity), SGLT2 inhibitors (Jardiance, Farxiga), DPP-4 inhibitors (Januvia, Tradjenta), and sulfonylureas (glipizide, glimepiride). The right choice depends on your kidney function, weight goals, and cardiovascular risk.

Can I substitute metformin with berberine? Berberine is a plant alkaloid sold as a supplement. Some studies show modest A1C reduction (0.5% to 1%) at high doses (1500 mg/day), but berberine is not FDA-approved for diabetes, dose-quality varies between products, and it is not a clinical equivalent to metformin. Discuss with a clinician before substituting any prescription drug with a supplement.

Is Ozempic a substitute for metformin? Yes, in many cases. Semaglutide (Ozempic) is a recognized first-line option for type 2 diabetes alongside or in place of metformin, especially for patients with BMI 27+ or established cardiovascular disease. The decision to use Ozempic instead of metformin is a clinical one.

Why would I need a metformin substitute? Common reasons: severe GI side effects, kidney function below 30 mL/min/1.73m², B12 deficiency, hepatic impairment, contrast dye exposure (temporary stop), or inadequate glucose control on metformin alone.

Is there an over-the-counter substitute for metformin? No. Metformin is a prescription drug and there are no FDA-approved OTC substitutes. Berberine and chromium picolinate are sometimes marketed as natural alternatives but neither is a clinical equivalent.

Can I substitute metformin during pregnancy? Metformin is generally considered safe in pregnancy, but some clinicians switch to insulin or GLP-1 agonists if metformin is not adequately controlling glucose. The decision is made with an obstetrician and endocrinologist together. (Note: GLP-1 agonists are generally avoided in pregnancy; insulin remains the gold standard for gestational diabetes.)

Is a sulfonylurea a good metformin substitute? For some patients, yes, especially when cost is a major factor. Sulfonylureas (glipizide, glimepiride) are inexpensive and effective at lowering A1C, but they cause hypoglycemia and weight gain. Current ADA guidelines prefer GLP-1 agonists or SGLT2 inhibitors first, with sulfonylureas as later-line options.

How fast can I switch from metformin to a substitute? Usually the next day. Most substitutes can be started without a wash-out period. The exceptions are GLP-1 agonists, where titration takes weeks to reach therapeutic dose. Recheck A1C at 3 months on the new agent.

Will my A1C go up when I stop metformin? Possibly, briefly, if the substitute doesn't cover metformin's full glucose-lowering effect. Most substitutes lower A1C as much as or more than metformin (especially GLP-1 agonists). Monitor blood glucose during the transition.

Is compounded semaglutide a metformin substitute? Functionally yes (same active ingredient as Ozempic), but compounded semaglutide is not FDA-approved. Brand-name semaglutide (Ozempic, Wegovy) is the FDA-approved version. Compounded products are prepared by 503A or 503B pharmacies in response to individual prescriptions.

Can I take metformin and a substitute together? That is not "substitution" but combination therapy, and it's often appropriate. Most diabetes guidelines actually recommend metformin plus a second agent (GLP-1 or SGLT2) over either drug alone for patients with cardiovascular disease or significant weight to lose.

Sources

1. American Diabetes Association. Standards of medical care in diabetes 2024. Diabetes Care. 2024;47(Suppl 1).
2. Maruthur NM, Tseng E, Hutfless S, et al. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2016;164:740-751.
3. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). N Engl J Med. 2016;375:1834-1844.
4. Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). N Engl J Med. 2021;385:503-515.
5. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes (EMPA-REG OUTCOME). N Engl J Med. 2015;373:2117-2128.
6. Heerspink HJL, Stefansson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease (DAPA-CKD). N Engl J Med. 2020;383:1436-1446.
7. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
8. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.
9. FDA. Metformin Prescribing Information. Revised 2023.
10. FDA. Drug safety communication: Revised warnings for metformin in reduced kidney function. April 2016.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Rybelsus, Victoza, and Saxenda are registered trademarks of Novo Nordisk A/S. Mounjaro, Zepbound, and Trulicity are registered trademarks of Eli Lilly and Company. Jardiance is a trademark of Boehringer Ingelheim. Farxiga is a trademark of AstraZeneca. Januvia and Tradjenta are trademarks of Merck and Boehringer Ingelheim respectively. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.